Cancer Archives

News and Trends 6 Jul 2015

ElsaLys Biotech grabs MABLife’s dual-acting antibody to treat cancer

French ElsaLys Biotech just acquired MABLife’s anti-CD160 antibody. Originally developed for the treatment of vascular eye diseases, the antibody also has the potential to be applied for tumor therapy. It inhibits vascular proliferation and modulates the immune system. To proliferate and migrate through the body, tumors rely on oxygen and nutrients supplies. Cancer cells initiate […]

July 6, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 3 Jul 2015

Lilly Cooperates with Immunocore to Fight Skin Cancer

Eli Lilly expands its portfolio in immune-oncology therapies. This time, Immunocore‘s lead T cell receptor-based drug, IMCgp100 is tested in combination with Lilly’s kinase inhibitors galunisertib and merestinib. This second collaboration between these two companies aims to increase drug efficacy against melanoma cancer. Melanomas are rare forms of skin cancer, that have a high potential […]

July 3, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 2 Jul 2015

Nanobiotix got the all-clear for its new Phase I/II clinical trial

The French National Agency for Medicines and Health Products gave Nanobiotix the green light to start a Phase I/II trial in two new cancer populations for its lead product, NBTXR3. This could lead to an increase in the commercial potential of this promising French Biotech. Nanobiotix is a great French Biotech company, which you can […]

July 2, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 1 Jul 2015

mRNA Therapies: CureVac Outperformed the Money Magnet Moderna

Everybody has already heard about Boston-based Moderna Therapeutics, the most highly valued venture-backed private Biotech, but CureVac, its German competitor, remains much more understated. This could rapidly change as CureVac just demonstrated that its technology beats Moderna’s. mRNA technologies could theoretically disrupt the whole drug industry. Imagine that you can directly inject mRNA into patients to make them produce their own therapeutic proteins. Unfortunately, […]

July 1, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 30 Jun 2015

Oldest French Biotech Transgene is One Step Closer to Bankruptcy

Transgene, the oldest French Biotech company announced just yesterday that it will cut 120 jobs on its current 300 employees. The company will shut down its manufacturing facility in order to focus on the Research and Development of its therapeutic vaccine candidates. Wise move or final last words? Back in 1976, Robert Swanson and Herbert Boyer founded […]

June 30, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 29 Jun 2015

6 Things the Digital Revolution already Disrupted in the Biotech Industry

2 weeks ago, I was at NOAH15 in Berlin, one of the biggest European events on Digital, gathering key opinion leaders such as Eric Schmidt from Google or Ariana Huffington, founder of the Huffington Post. They all talked about the impact of the recent digital wave, internet and the post-pc area in different industries. Biotech […]

June 29, 2015 - 6 minutesmins - By Philip Hemme

News and Trends 25 Jun 2015

BioNTech and Siemens to build a new Production plant for Personalized Cancer Vaccines

Personalized medicine is the next thing and immunotherapy expert BioNTech is determined to build its place in this competitive field. With this purpose in mind, the German biotech will partner with Siemens to build a new production plant for personalized cancer vaccines. Founded in 2008, the BioNTech Group has become one of the fastest-growing biotechnology […]

June 25, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 19 Jun 2015

Servier disburses €114 Million for Taiho’s Colorectal Cancer treatment

Servier is fattening up its oncology assests with the acquisition of Taiho Pharmaceutical’s treatment of refractory mestatic colorectal cancer. The French laboratories will commercialize the molecule in Europe and other countries. Taiho Pharmaceutical and Servier come to an agreement for the development and commercialization of TAS-102 in Europe. The drug is an oral combination anticancer drug […]

June 19, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 17 Jun 2015

Innovate UK accelerates Sareum’s fight against Leukemia

Innovate UK, the country’s innovation agency, keeps promoting technology in the British islands. The latest beneficiary is Sareum, a cancer specialist biotech with a strong autoimmune disease programme. The company received €195.5k to fight an early-age type of leukaemia. T-Cell Acute Lymphoblastic Leukaemia is a rare type of leukaemia that most often occurs in late […]

June 17, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 15 Jun 2015

Jonhson&Jonhson hurries up Genmab’s myeloma treatment

Genmab and its partner Jonhson&Jonhson, through its subsidiary Janssen Biotech, are trying to speed up daratumumab. The companies initiated a rolling submission for the candidate that targets multiple myeloma. The German-American partnership is trying to accelerate the arrival of daratumumab to the market, only just after the presentation of optimistic results of MOR202’s phase I/IIa. […]

June 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 12 Jun 2015

Polaris, a new Nordic leader in Immuno-Oncology

Immuno-oncology is a busy market to take on by yourself due to the existing fierce competition. Targovax and Oncos Therapeutics have decided to merge to earn a spot in the field. Polaris, the combined business, contemplates a private placement of around €15M to fund the freshly baked company. Finland and Norway never were this close as Oncos […]

June 12, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 10 Jun 2015

French collaboration to develop Oncology-targeted Therapy

PEP-Therapy and CleveXel Pharma will co-develop targeted therapy in oncology. The product is based on an innovative technology involving bi-functional peptides that penetrate cells, and specifically block pathological mechanisms without affecting physiological mechanisms. The drug candidate is a cell-penetrating peptide that targets an interaction between two intracellular proteins, Caspase-9 and PP2A. It has been validated […]

June 10, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

ElsaLys Biotech grabs MABLife’s dual-acting antibody to treat cancer

Lilly Cooperates with Immunocore to Fight Skin Cancer

Nanobiotix got the all-clear for its new Phase I/II clinical trial

mRNA Therapies: CureVac Outperformed the Money Magnet Moderna

Oldest French Biotech Transgene is One Step Closer to Bankruptcy

6 Things the Digital Revolution already Disrupted in the Biotech Industry

BioNTech and Siemens to build a new Production plant for Personalized Cancer Vaccines

Servier disburses €114 Million for Taiho’s Colorectal Cancer treatment

Innovate UK accelerates Sareum’s fight against Leukemia

Jonhson&Jonhson hurries up Genmab’s myeloma treatment

Polaris, a new Nordic leader in Immuno-Oncology

French collaboration to develop Oncology-targeted Therapy

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!